[go: up one dir, main page]

AU2001229441A1 - Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease - Google Patents

Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease

Info

Publication number
AU2001229441A1
AU2001229441A1 AU2001229441A AU2944101A AU2001229441A1 AU 2001229441 A1 AU2001229441 A1 AU 2001229441A1 AU 2001229441 A AU2001229441 A AU 2001229441A AU 2944101 A AU2944101 A AU 2944101A AU 2001229441 A1 AU2001229441 A1 AU 2001229441A1
Authority
AU
Australia
Prior art keywords
pai
asthma
antagonists
treatment
pulmonary disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001229441A
Inventor
Seong H. Cho
Sossiena Demissie-Sanders (Nmi)
Chad K. Oh
Sunny W. Tan
David W Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanox Inc
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of AU2001229441A1 publication Critical patent/AU2001229441A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/417Imidazole-alkylamines, e.g. histamine, phentolamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001229441A 2000-01-14 2001-01-12 Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease Abandoned AU2001229441A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17621100P 2000-01-14 2000-01-14
US60176211 2000-01-14
PCT/US2001/001158 WO2001051085A1 (en) 2000-01-14 2001-01-12 Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease

Publications (1)

Publication Number Publication Date
AU2001229441A1 true AU2001229441A1 (en) 2001-07-24

Family

ID=22643429

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001229441A Abandoned AU2001229441A1 (en) 2000-01-14 2001-01-12 Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease

Country Status (3)

Country Link
US (1) US6767540B2 (en)
AU (1) AU2001229441A1 (en)
WO (1) WO2001051085A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500019B1 (en) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm USE IN VITRO OF THE TRANSCRIPTION FACTOR NAK-1 OR NAK-1 REGULATED GENES FOR THE DIAGNOSIS OF INFLAMMATORY AND MALIGNIC DISEASES
US20030199463A1 (en) 2002-04-23 2003-10-23 Silviu Itescu DNA enzyme to inhibit plasminogen activator inhibitor-1
US20050069909A1 (en) * 2002-12-31 2005-03-31 Boehringer Ingelheim Pharmaceuticals, Inc. Method to identify and analyze genes having modified expression in activated cells with secretory lysosomes
ES2346881T3 (en) * 2003-03-19 2010-10-21 The University Of British Columbia HIPLOTIPOS OF THE INHIBITOR OF THE PLASMINOGEN ACTIVATOR 1 (PAI-1) USEFUL AS PATIENT RESULT INDICATORS.
US20060286084A1 (en) * 2003-09-30 2006-12-21 Yoshikazu Morita Agent for promoting osteogenesis and/or inhibiting bone resorption
CA2680589A1 (en) * 2007-03-14 2008-09-18 Universita' Degli Studi Di Milano - Bicocca Modulator compounds of the drug resistance in epithelial tumour cells
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
WO2009033095A2 (en) * 2007-09-07 2009-03-12 Cisthera, Incorporated Humanized pai-1 antibodies
WO2011139974A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN112142845A (en) * 2013-08-13 2020-12-29 赛诺菲 Plasminogen activator inhibitor-1 (PAI-1) antibody and use thereof
US20220105068A1 (en) * 2018-09-13 2022-04-07 Eirion Therapeutics, Inc. Plasminogen activator inhibitor 1 (pai-1) inhibitors and uses therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3742997A1 (en) * 1987-12-18 1989-06-29 Behringwerke Ag PEPTIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE FOR THE OBTAINING OF ANTIBODIES, AND THEIR USE FOR BLOCKING THE PAI-1 ACTIVITY OF HUMAN BLOOD
WO1995030438A2 (en) * 1994-05-10 1995-11-16 Hamilton Civic Hospitals Research Development, Inc. Methods and compositions to enhance endogenous fibrinolytic activity
DE19742717A1 (en) * 1997-09-26 1999-04-01 Knoll Ag Synergistic combination of endothelin antagonist and renin-angiotensin system inhibitor

Also Published As

Publication number Publication date
US6767540B2 (en) 2004-07-27
WO2001051085A1 (en) 2001-07-19
US20020086838A1 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
GB2366800B (en) Antibody molecules having specificity for human tumor necrosis factor alpha,and use thereof
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AU2003297681A8 (en) Abrasive webs and methods of making the same
AU2002321872A1 (en) Abrasive particles, and methods of making and using the same
AU2002363797A1 (en) Compression garment for selective application of treatment of lymphedema and related illnesses manifested at various location of the body
AU2002319749A1 (en) Ceramic materials, abrasive particles, abrasive articles, and methods of making and using the same
ZA200402858B (en) Novel beta-phenyl-alpha-oxysubstituted propionic derivatives; process for its preparation and their use in the preparation of pharmaceutically important compounds.
AU2001229441A1 (en) Use of antagonists of plasminogen activator inhibitor-1 (pai-1) for the treatment of asthma and chronic obstructive pulmonary disease
EP1478748A4 (en) Fce fusion proteins for treatment of allergy and asthma
AU2002343094A1 (en) Use of ppar activators for the treatment of pulmonary fibrosis
AU6083899A (en) Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
AU2001233757A1 (en) Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases
EP1448185A4 (en) Treating asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties
HU0102388D0 (en) Diazepinoindoles for the treatment of chronic obstructive pulmonary disease
EP1364031A4 (en) Hiv-like particles and the use thereof
AU2002219473A1 (en) Treatment of asthma and other lung conditions
AU2002339682A1 (en) Emergen agonists and antagonists for use in the treatment of metabolic disorders
AU2002222169A1 (en) Proteins, genes and their use for diagnosis and treatment of chronic asthma
GB0127010D0 (en) Valve joint and the process of its manufacture
HK1069103A (en) Treating asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties
HK1065026A (en) Materials and methods for the production and purification of chlorofluorocarbons and hydrofluorocarbons
AU2003241051A1 (en) Use of shp-1 for the therapy of asthma
AU2002307114A1 (en) Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
AU2002330299A1 (en) Antibody and use of the same
AU2002301208A1 (en) Use of coagulation factor VII - activating protease for the prophylaxis and therapy of vasoproliferative disorders